Medesis Pharma (STU:76D) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Medesis Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medesis Pharma's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Medesis Pharma ROCE % Historical Data

The historical data trend for Medesis Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma ROCE % Chart

Medesis Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-126.24

-425.93

-240.82

Medesis Pharma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial						-196.20	-485.29	-	-	-

Medesis Pharma ROCE % Calculation

Medesis Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.141	/	( ( (1.916 - 1.932)	+	(1.926 - 4.051) )	/ 2 )
	=	-4.141	/	( (-0.016	+	-2.125)	/ 2 )
	=	-4.141	/	-1.0705
	=	386.83 %

Medesis Pharma's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-1.79	/	( ( (1.926 - 4.051)	+	(2.106 - 5.037) )	/ 2 )
	=	-1.79	/	( ( -2.125	+	-2.931 )	/ 2 )
	=	-1.79	/	-2.528
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Medesis Pharma (STU:76D) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medesis Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medesis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (STU:76D) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALMDP:France 76D:Germany

Address

Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670

Website

https://www.medesispharma.com

Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines